GlassScriptPhysician profile
Tracy W Flory
NPI 1932145125
$5,317.46
in general payments reported to CMS, 2019-2025
31 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $692 · 2022: $798 · 2023: $1,211 · 2024: $1,242 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,827.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,057.16 | 2021-2025 | |
| Novo Nordisk INC | $954.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $648.50 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $530.11 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $450.13 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.94 | 2021-2025 | Jardiance |
| Amgen INC. | $270.57 | 2021-2025 | Otezla, Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $143.74 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $110.60 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $94.99 | 2023-2025 | Rexulti |
| Boston Scientific Corporation | $78.80 | 2021-2024 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Sanofi-Aventis U.S. LLC | $68.04 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.96 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $58.02 | 2021 | |
| Axsome Therapeutics, INC. | $53.14 | 2025 | Auvelity, Sunosi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $45.43 | 2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $44.30 | 2025 | |
| Ironshore Pharmaceuticals INC. | $44.22 | 2023-2024 | Jornay Pm |
| Axonics, INC. | $39.71 | 2024 | Axonics |
| Teva Pharmaceuticals USA, INC. | $36.13 | 2023 | Austedo Xr, Ajovy |
| Esperion Therapeutics, INC. | $34.31 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.53 | 2021 | |
| Glaxosmithkline, LLC. | $28.00 | 2021-2025 | Trelegy Ellipta |
| Collegium Pharmaceutical, INC. | $21.59 | 2025 | Jornay Pm |
| Vertex Pharmaceuticals Incorporated | $21.25 | 2025 | |
| Upsher-Smith Laboratories LLC | $20.66 | 2021 | |
| Stryker Corporation | $19.41 | 2025 | Mako |
| Nestle Healthcare Nutrition INC. | $18.19 | 2021 | |
| Lundbeck LLC | $15.30 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $13.18 | 2021 | |
| Amarin Pharma, INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Flory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.